公开(公告)号：US20130028974A1

公开(公告)日：2013-01-31

申请号：US13640590

申请日：2011-05-13

申请人： Yong Il Kim ,  Young Jun Na ,  Min Jung Kim ,  Young-Hun Kim ,  Jae Hyun Park ,  Jong Soo Woo

发明人： Yong Il Kim ,  Young Jun Na ,  Min Jung Kim ,  Young-Hun Kim ,  Jae Hyun Park ,  Jong Soo Woo

IPC分类号： A61K31/4184 ,  A61P3/06 ,  A61K9/20

CPC分类号： A61K31/40 ,  A61K9/1611 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2054 ,  A61K9/209 ,  A61K31/415 ,  A61K45/06 ,  A61K2300/00

摘要： Provided is a pharmaceutical formulation in the form of a bilayered tablet consisting of a first layer containing irbesartan or a pharmaceutically acceptable salt thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia.

摘要翻译： 本发明提供了由含有厄贝沙坦或其药学上可接受的盐的第一层和含有HMG-CoA还原酶抑制剂和碱性添加剂的第二层组成的双层片形式的药物制剂，其可以提高溶出速率和稳定性 厄贝沙坦和HMG-CoA还原酶抑制剂，以增强与常规复合制剂相比药物的生物利用度，并使相关化合物的产生最小化，从而有效地用作高血压和高胆固醇血症的稳定和优越的治疗剂。

公开(公告)号：US09694007B2

公开(公告)日：2017-07-04

申请号：US13576338

申请日：2011-01-18

申请人： Jong Soo Woo ,  Jae Hyun Park ,  Yong Il Kim ,  Young Jun Na ,  Min Jung Kim ,  Yun Ah Lee

发明人： Jong Soo Woo ,  Jae Hyun Park ,  Yong Il Kim ,  Young Jun Na ,  Min Jung Kim ,  Yun Ah Lee

IPC分类号： A61K9/28 ,  A61K31/495 ,  A61K9/24 ,  A61K31/137

CPC分类号： A61K31/495 ,  A61K9/209 ,  A61K31/137 ,  A61K2300/00

摘要： An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.

公开(公告)号：US20130243872A1

公开(公告)日：2013-09-19

申请号：US13988947

申请日：2011-12-14

申请人： Yong Il Kim ,  Young Jun Na ,  Jun Young Choi ,  Min Jung Kim ,  Jae Hyun Park ,  Jong Soo Woo

发明人： Yong Il Kim ,  Young Jun Na ,  Jun Young Choi ,  Min Jung Kim ,  Jae Hyun Park ,  Jong Soo Woo

IPC分类号： A61K9/16 ,  A61K31/40 ,  G01N33/15 ,  A61K31/616

CPC分类号： A61K9/16 ,  A61K9/1611 ,  A61K9/1676 ,  A61K9/4808 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/47 ,  A61K31/505 ,  A61K31/616 ,  A61K45/06 ,  G01N33/15 ,  A61K2300/00

摘要： Provided is a pharmaceutical composite formulation for preventing or treating cardiovascular diseases, which comprises (1) a first particle comprising an HMG-CoA reductase inhibitor and a basic additive; and (2) a second particle comprising a core containing aspirin and an enteric coating layer coated on said core, wherein the difference in the average diameters of said first and second particles is 100 μm to 800 μm; a method for preparing same; and a method of validating the quality of same. The pharmaceutical composite formulation according to the present invention can improve the stability of an active ingredient and prevent adverse impacts between the active ingredients to thereby enable an accurate quality validation of the pharmaceutical composite formulation.

摘要翻译： 提供一种用于预防或治疗心血管疾病的药物复合制剂，其包含（1）包含HMG-CoA还原酶抑制剂和碱性添加剂的第一颗粒; 和（2）包含含有阿司匹林的芯和涂覆在所述芯上的肠溶衣层的第二颗粒，其中所述第一和第二颗粒的​​平均直径的差异为100μm至800μm; 一种制备方法; 以及验证其质量的方法。 根据本发明的药物复合制剂可以改善活性成分的稳定性并防止活性成分之间的不利影响，从而能够对药物复合制剂进行准确的质量验证。

公开(公告)号：US20120301548A1

公开(公告)日：2012-11-29

申请号：US13576338

申请日：2011-01-18

申请人： Jong Soo Woo ,  Jae Hyun Park ,  Yong Il Kim ,  Young Jun Na ,  Min Jung Kim ,  Yun Ah Lee

发明人： Jong Soo Woo ,  Jae Hyun Park ,  Yong Il Kim ,  Young Jun Na ,  Min Jung Kim ,  Yun Ah Lee

IPC分类号： A61K9/50 ,  A61P37/08 ,  A61P11/00 ,  A61K31/495

CPC分类号： A61K31/495 ,  A61K9/209 ,  A61K31/137 ,  A61K2300/00

摘要： An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.

摘要翻译： 口服复合物组合物，其包含（i）包含可溶胀水凝胶形成剂和伪麻黄碱的核心或其药学上可接受的盐; （ii）包含芯的第一涂层，其包含水溶性物质; 和（iii）在聚乙烯醇，聚维酮，聚乙烯醇 - 聚乙二醇接枝共聚物或它们的混合物上，包含左西替利嗪或其药学上可接受的盐，沉积在第一涂层上的第二涂层具有改善的左西替利嗪释放速率，并且不显示 延迟释放行为即使在长期储存期后。 因此，本发明的口服复合物组合物可用于治疗多发性或季节性过敏性疾病，包括鼻塞，打喷嚏和鼻漏。

公开(公告)号：US20120301549A1

公开(公告)日：2012-11-29

申请号：US13576585

申请日：2011-01-26

申请人： Jong Soo Woo ,  Jae Hyun Park ,  Yong Il Kim ,  Young Jun Na ,  Jun Young Choi ,  Yun Ah Lee

发明人： Jong Soo Woo ,  Jae Hyun Park ,  Yong Il Kim ,  Young Jun Na ,  Jun Young Choi ,  Yun Ah Lee

IPC分类号： A61K9/50 ,  A61P9/00 ,  A61K31/60

CPC分类号： A61K31/40 ,  A61K9/1652 ,  A61K9/5063 ,  A61K9/5084 ,  A61K31/505 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

摘要： Provided is a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor, which has improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase which is caused by salicylic acid, thereby being used in the treatment of hypertension and hypercholesterolemia.

摘要翻译： 提供了用于预防或治疗心血管疾病的复合制剂，其包括：a）涂覆有含有疏水性添加剂的屏障的阿司匹林; 和b）HMG-CoA还原酶抑制剂，通过防止由水杨酸引起的HMG-CoA还原酶的稳定性降低而提高储存稳定性，从而用于治疗高血压和高胆固醇血症。